Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result
- Conditions
- Prostatic Neoplasms
- Interventions
- Other: PCA3 Assay
- Registration Number
- NCT01024959
- Lead Sponsor
- Gen-Probe, Incorporated
- Brief Summary
The objective of this multi-center clinical study is to determine the association of the PCA3 Score with prostate biopsy outcome and validate the assay's performance characteristics in men with previous negative prostate biopsies. An elevated PCA3 Score is thought to be associated with an increased likelihood of positive biopsy. The results of this study are intended to be used for regulatory filings for use as an in vitro diagnostic test.
- Detailed Description
PCA3 is a gene that is highly over-expressed in more than 90% of prostate cancers, and that can be quantified in urine specimens following a digital rectal examination. Studies have shown that because PCA3 is highly specific for prostate cancer, it predicts the results of repeat biopsies more accurately than traditional prostate-specific antigen (PSA) testing. Gen-Probe's PROGENSA(R) PCA3 assay is the first urine-based molecular diagnostic assay for prostate cancer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 507
- Men 40+ years of age who have had at least 1 previous negative prostate biopsy, who have never had a positive prostate biopsy, and who have been recommended for a repeat biopsy by their clinician.
- The subject must be able to comprehend and sign an approved informed consent form and other applicable study enrollment documents
- Use of medications or hormones that are known to affect serum PSA levels within 3 - 6 months of study enrollment
- Clinical symptoms of urinary tract infection (including prostatitis) at the time of enrollment
- History of prostate cancer
- History of invasive treatments for benign prostatic hypertrophy (BPH) or lower urinary tract symptoms within 6 months of study enrollment
- Medical history or concurrent illness that the investigator considers sufficiently serious to interfere with the conduct, completion, or results of this trial, or constitutes an unacceptable risk to the subject
- Participation in pharmaceutical or treatment related clinical study within 6 months of study enrollment. Exception: Trials for non-prostate conditions may be acceptable, with approval by the investigator and Sponsor
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PCA3 Assay PCA3 Assay -
- Primary Outcome Measures
Name Time Method Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.) At the time of biopsy The likelihood of positive biopsy was determined by the PCA3 Score expressed as a binary categorical variable: PCA3 Score \>=25 was positive, PCA3 Score \<25 was negative
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (13)
South Florida Medical Research
๐บ๐ธAventura, Florida, United States
Florida Urology Specialists
๐บ๐ธSarasota, Florida, United States
Regional Urology Specialists, LLC
๐บ๐ธShreveport, Louisiana, United States
MD Anderson Cancer Center
๐บ๐ธHouston, Texas, United States
San Diego Clinical Trials
๐บ๐ธSan Diego, California, United States
HealthCare Partners Medical Group
๐บ๐ธLos Angeles, California, United States
Specialists in Urology
๐บ๐ธNaples, Florida, United States
TriState Urologic Services PSC Inc. dba The Urology Group
๐บ๐ธCincinnati, Ohio, United States
AccuMed Research Associates
๐บ๐ธGarden City, New York, United States
Metropolitan Urology, PSC
๐บ๐ธJeffersonville, Indiana, United States
Columbus Urology Research, LLC
๐บ๐ธColumbus, Ohio, United States
Urology San Antonio Research
๐บ๐ธSan Antonio, Texas, United States
Virginia Urology
๐บ๐ธRichmond, Virginia, United States